Early Detection of Broken Hearts in Cancer Patients

Overview

  • Study type

    Observational
  • Study IDs

  • Describes the nature of a clinical study. Types include:

    • Observational study — observes people and measures outcomes without affecting results.
    • Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
    • Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
  • Site IRB
    • Rochester, Minnesota: 12-005362
    NCT ID: NCT02086695
    Sponsor Protocol Number: 12-005362

About this study

The early detection of Bevacizumab or Sunitinib caused cardiotoxicity using cardiac biomarkers and new Transthoracic Echocardiogram (TTE) techniques may allow the adjustment of treatment and/or the administration of prophylactic heart protective agents, prior to the development of irreversible cardiac dysfunction. We hypothesize that cardiac biomarkers, TVI/strain-derived indices will be able to accurately detect subtle cardiac injury at a time when conventional Left Ventricular Ejection Fraction (LVEF) remains normal.  Additionally, we hypothesize that Endothelial Function Test (EndoPAT) testing can detect early endothelial dysfunction.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

See eligibility criteria

Inclusion Criteria

  • Patients with advanced cancer
  • Treatment plan includes Bevacizumab ,Sunitinib, or Pazopanib
  • Ages 18 - 90 years old

Exclusion Criteria

  • Left Ventricular EF < 50%

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Sharon Mulvagh, M.D.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

855-776-0015

.
CLS-20167667

Mayo Clinic Footer